Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
about
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancerSignaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsInternal radiation therapy: a neglected aspect of nuclear medicine in the molecular eraSorafenib in metastatic thyroid cancer: a systematic reviewTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsPersonalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterationsRaf-interactome in tuning the complexity and diversity of Raf function.Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancerSelumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK PathwayUpdate: the status of clinical trials with kinase inhibitors in thyroid cancerPopulation Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's ThyroiditisA potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionMEK and the inhibitors: from bench to bedside.MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroMultikinase inhibitors use in differentiated thyroid carcinoma.BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerDifferentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis.New therapies for dedifferentiated papillary thyroid cancerThe Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese PatientsSimultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancerAberrant expression of COT is related to recurrence of papillary thyroid cancer.Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.Modeling of lamin A/C mutation premature cardiac aging using patient‐specific induced pluripotent stem cells.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.Evolving approaches to patients with advanced differentiated thyroid cancerNew molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature reviewThat which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.New therapeutic options for advanced forms of thyroid cancer.Prospects for MEK inhibitors for treating cancer.New RAF kinase inhibitors in cancer therapy.The biology and clinical development of MEK inhibitors for cancer.Advances in thyroid cancer treatment: latest evidence and clinical potential.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
P2860
Q24596266-509028D9-C7CD-44E8-8F27-E84E2348F53FQ26764899-ACE0D1DC-CA41-4C5D-8D56-D8802B1EA9DEQ26786554-ED663567-2999-42A9-AD1A-3FC4D46C111AQ26828884-3338C126-7662-4C84-97D2-312252DF9E73Q26862841-E60BD23E-5AE7-42F1-9EAC-ADA36A41FA10Q26863326-286B755E-7D7D-4AB3-AEA6-8ECF9A1270DDQ27027491-FCD99ACB-B6BD-44B3-AE54-B442E055397BQ27692653-2B9FC2AE-674C-4F9A-B9B6-DECC0AD12708Q27852623-880D902A-1D5E-4F4E-9153-BB16B59A18FFQ28072655-82916582-6D55-4A9A-8E0F-DEE7F56000DFQ28552721-25995230-0557-4273-90FC-05FFFA91A4BAQ33570056-0B582D14-8AD1-4161-98B4-AACA382F40F0Q33729778-4C8A7873-FDC4-41E6-B0CB-286EEF44E628Q33875906-475E9FAC-1DD7-42AA-B05E-B85F2C0949ECQ33884794-163D0217-D3E4-46EC-B985-DE76B2ADE52AQ33931434-A48B5267-6927-438F-9837-51A15D2081CBQ34036341-10962555-7F51-4164-BE0C-E812F2927DC7Q34615021-B5DA33FF-FAED-426C-B349-7FB2D097282AQ34660901-85AAB9F1-3537-4B09-9C1A-BA1C304767C1Q34919430-E1435752-A337-47A6-AB9C-93A78118D905Q35057314-B49EB2AC-D7C3-41BC-A945-C8F814285BB7Q35323457-51840D74-F1EE-42E5-8E36-3C77756E44C1Q35381593-FA5F549E-B042-4473-BED5-3DDD02F62965Q35932262-C994D73E-5519-4E19-B09E-02B86C02A509Q36012586-91EEF239-0EEC-49BD-ADFC-D3DD1E2CDCC1Q36152396-19E85939-BC53-4D38-AB35-E26164E38C6CQ36280358-45B48971-E2CA-4649-BD25-26BDFFF8AC86Q36576360-DDFDDD73-C5D4-409D-83DF-949970A4F582Q36736494-3AC6C74B-1B69-4BF5-936E-369FB1FEA10FQ36836677-42093FB9-FCA7-4501-B8B0-2BB4379C3B8FQ36864736-BC75F628-F68B-4407-9568-AC62775DC86EQ38074169-0E82D7FE-5961-42A8-A4B0-A9D37CCC3836Q38104439-42D568BD-DB13-47BE-AE12-4F659B5F8E3BQ38192680-99714438-5713-45C1-A52E-D29B1643587CQ38193520-51B474C4-0C61-4211-9774-D8E0A4DBC0F0Q38207082-90A5BCE7-4760-4680-9638-00059FB5CD94Q38270129-0E0684FD-4794-4DA1-A577-B49E34C26639Q38305056-44C2FEE5-251D-41C4-92A4-6DE9363B5AD1Q38554422-FFE12BF9-97EC-4FF9-9046-449CA3C6094FQ38579925-0883BDE7-3850-4EF1-BE05-51CBF6C229DE
P2860
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II efficacy and pharmaco ...... or without follicular elements
@en
Phase II efficacy and pharmacogenomic study of Selumetinib
@nl
type
label
Phase II efficacy and pharmaco ...... or without follicular elements
@en
Phase II efficacy and pharmacogenomic study of Selumetinib
@nl
prefLabel
Phase II efficacy and pharmaco ...... or without follicular elements
@en
Phase II efficacy and pharmacogenomic study of Selumetinib
@nl
P2093
P2860
P50
P1476
Phase II efficacy and pharmaco ...... or without follicular elements
@en
P2093
Amy S Lucas
Arif Sheikh
Barbara A Murphy
Christine H Chung
Dominic T Moore
Ezra E W Cohen
Janelle Hoskins
Jill Gilbert
Michele C Hayward
P2860
P304
P356
10.1158/1078-0432.CCR-11-0563
P407
P577
2012-01-12T00:00:00Z